Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) FCF Margin (2019 - 2025)

Historic FCF Margin for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to 987.37%.

  • Kymera Therapeutics' FCF Margin rose 3491900.0% to 987.37% in Q3 2025 from the same period last year, while for Sep 2025 it was 96725.63%, marking a year-over-year increase of 968948800.0%. This contributed to the annual value of 6688.35% for FY2024, which is 65136500.0% down from last year.
  • As of Q3 2025, Kymera Therapeutics' FCF Margin stood at 987.37%, which was up 3491900.0% from 527.88% recorded in Q2 2025.
  • Kymera Therapeutics' 5-year FCF Margin high stood at 171.47% for Q4 2024, and its period low was 1336.57% during Q3 2024.
  • Its 5-year average for FCF Margin is 391.28%, with a median of 344.97% in 2022.
  • Its FCF Margin has fluctuated over the past 5 years, first plummeted by -10741400bps in 2021, then soared by 3491900bps in 2025.
  • Quarter analysis of 5 years shows Kymera Therapeutics' FCF Margin stood at 254.36% in 2021, then grew by 3bps to 247.28% in 2022, then skyrocketed by 97bps to 7.48% in 2023, then soared by 2394bps to 171.47% in 2024, then crashed by -676bps to 987.37% in 2025.
  • Its last three reported values are 987.37% in Q3 2025, 527.88% for Q2 2025, and 360.26% during Q1 2025.